EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Interactive Labs · Everything I Take

Add up everything you take, in one set of units, against the published upper limits.

Find a product in the NIH label database, paste a Supplement Facts panel, add foods from USDA data or enter ingredients one by one. The calculator converts IU, folate, vitamin A forms and mineral salts into the amounts the reference values use, totals everything, and shows each nutrient against the U.S. and EU upper levels for your life stage.

A calculator, not advice. It adds what you list and compares the totals with published reference values. It does not check your medicines, diagnose or recommend anything. Your list stays in this browser; a label search sends only your search words to the NIH database. What it does not do

Schematic, Everything I Take, in three steps: Add what you take Read a label, find a product or type an ingredient Units converted IU, folate, vitamin A forms, mineral salts Totals against upper limits U.S. and EU values for your life stage Free. No account. Your list stays in your browser. A calculator, not medical advice.
Schematic How the calculator works, drawn by EUTECNIQ. It adds what you list; it does not check your medicines.

Calculator

Upper levels to show

Stored only in this browser · no account · no tracking

1 · Add what you take

2 · Your list

    3 · Your daily totals ·

    EUTECNIQ Atlas · Everything I Take · printed . A list of what I take and its totals against published reference values; not medical advice.

    Your totals will show here as dials and bars

    Add a product on the left, or load the worked example to see how the calculator reads it.

    Against the upper levels
    • U.S. UL (NASEM)
    • EU UL or safe level (EFSA, adults)
    • RDA or AI
    • Caffeine, EGCG or monacolin reference
    • Bar colors: your products, in the order listed
    Show every total as a tableYour totals, the reference values and what each upper level covers
    Every total, its reference values and what each upper level covers
    NutrientYour total a dayRDA or AI · shareU.S. UL · shareEU value · shareWhat the values cover

    Explore

    How wide is the window between enough and too much?

    For each nutrient: the upper level divided by the recommended amount (the RDA, or the AI where no RDA is set). A narrow window means a few products together can pass the upper level. These are the values the calculator uses.

    Window width for one life stage

    Tap a nutrient to see it across every life stage.

    • Turn on JavaScript to draw this chart.

    Upper level covers total intake* Upper level covers only part of intake (for example, supplements only), so the width is not like for like

    One nutrient across life stages

      RDA or AIWindow up to the upper levelUpper level

      Values: U.S. Dietary Reference Intakes (NASEM), as listed under Reference values and sources. A wide window is not a reason to take more.

      How interactions happen

      How a botanical can change what a medicine does

      Most documented botanical–drug interactions run through a few mechanisms: the enzymes that break medicines down, the transporters that carry them across the gut wall, a shared active substance, or an added effect on the same body system. The calculator does not check your medicines. This explainer shows the mechanism and the measured size of the best-documented examples, each with its source.

      Show the mechanisms, with measured examplesEnzymes, transporters, shared substances and added effects; 8 botanicals and foods, with sources
      Where a medicine taken by mouth can be changed on its way to the blood
      A medicine taken by mouth passes from the gut into the gut-wall cells, where the uptake transporter OATP carries it in, the efflux pump P-gp pushes it back, and the enzyme CYP3A4 breaks part of it down; it then travels in the portal vein to liver cells, where CYP3A4 breaks down more, and the amount of CYP3A4 is set by the PXR receptor in the nucleus; what is left reaches the blood. Inhibiting an enzyme raises the amount that reaches the blood; inducing an enzyme or blocking uptake lowers it. Gut medicine Gut-wall cell OATP carries it in P-gp pumps it back CYP3A4 breaks it down portalvein Liver cell CYP3A4 breaks it down nucleus: PXRsets how muchCYP3A4 is made Blood whatis left
      • Inhibition · goldenseal, grapefruit juice: less of the medicine is broken down, so more reaches the blood.
      • Induction · St. John’s wort (hyperforin activates PXR): more CYP3A4 is made, so less reaches the blood.
      • Uptake blocked · green tea (nadolol), grapefruit juice (fexofenadine): less is carried in, so less is absorbed.
      Simplified schematic: the same enzymes and transporters also act in other organs, and many medicines use other enzymes (CYP2D6, CYP1A2 and others). Sources in the cards below.

      Enzyme induction

      St. John’s wort

      Hyperforin, a constituent of St. John’s wort, binds the pregnane X receptor (PXR) with an inhibition constant of 27 nM. In human liver cells, hypericum extracts or hyperforin markedly induced CYP3A4, an enzyme involved in the oxidative metabolism of more than half of all drugs1.

      FDA lists St. John’s wort as a strong CYP3A inducer, a class defined as lowering the exposure (AUC) of sensitive substrates by 80% or more, and notes that its effect varies widely and depends on the preparation2. It can weaken the effects of many medicines, including birth control pills, cyclosporine, digoxin and some HIV drugs3.

      Direction: less of the medicine in the blood.

      Enzyme inhibition · transporters

      Goldenseal

      After 14 days of goldenseal, exposure to midazolam (a CYP3A probe drug) rose from 107.9 to 175.3 ng·h/mL in 16 healthy volunteers4. In an NIH-funded study of 16 volunteers, goldenseal raised midazolam exposure by a geometric mean ratio of 1.43 and lowered metformin exposure to 0.77 of its usual value; the authors describe goldenseal as inhibiting CYP3A and CYP2D65.

      NCCIH describes the metformin drop, about 25 percent, as enough to potentially hinder glucose control in people with type 2 diabetes6.

      Direction: more of some medicines, less of others.

      Gut-wall enzyme inhibition · transporters

      Grapefruit juice

      Grapefruit juice can block the action of CYP3A4 in the small intestine, so more of some drugs, such as certain statins, enters the blood and stays in the body longer. For a few drugs, such as fexofenadine, it has the opposite effect through drug transporters: less of the drug enters the blood7.

      FDA lists grapefruit juice as a moderate CYP3A inhibitor (raising the exposure of sensitive substrates 2- to under 5-fold); its effect varies among brands and depends on concentration, dose and preparation2.

      Direction: usually more medicine in the blood; less for a few.

      Uptake transporter

      Green tea

      Ten healthy volunteers drank 700 mL of green tea a day for 14 days. The peak concentration and exposure of a single 30 mg dose of nadolol fell by 85.3% and 85.0%, without a change in its renal clearance, and nadolol’s effect on systolic blood pressure was significantly reduced8. In cell assays, green tea inhibited nadolol uptake by the transporter OATP1A2, which the authors suggest explains the effect in part, in the intestine8. Nadolol is also a P-glycoprotein substrate9.

      NCCIH adds that green tea extract can reduce blood levels of atorvastatin and that an interaction with raloxifene has been shown10.

      Direction: less of the medicine in the blood.

      Same active substance

      Red yeast rice

      Monacolin K is structurally identical to the statin lovastatin, so red yeast rice products with significant amounts of it can have the same side effects and the same types of drug interactions as statins11. FDA lists lovastatin as a sensitive CYP3A substrate, a drug whose exposure rises 5-fold or more with strong inhibitors of that pathway2.

      In 26 U.S. brands that contained monacolin K, the amount ranged from 0.09 to 5.48 mg per 1,200 mg of red yeast rice, and none stated it on the label11.

      Direction: a hidden extra dose of a statin.

      Added effect

      Garlic

      Taking garlic supplements may increase the risk of bleeding, which matters for people taking anticoagulants or aspirin and before surgery12. This is not a change in the medicine’s level but two effects on the same system adding together.

      Direction: a larger combined effect.

      Enzyme substrate

      Caffeine

      Caffeine is broken down mainly by CYP1A2: FDA lists it as a sensitive CYP1A2 substrate, and lists the antidepressant fluvoxamine as a strong CYP1A2 inhibitor2. NCCIH notes theoretical reasons to suspect that echinacea might interact with caffeine13.

      Direction: an inhibitor of CYP1A2 can make caffeine last longer.

      1. Moore LB et al. St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. PNAS 2000;97:7500–7502. PubMed 10852961
      2. FDA. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers (content current as of May 29, 2026). fda.gov
      3. NCCIH. St. John’s wort (May 2025). nccih.nih.gov
      4. Gurley BJ et al. Supplementation with goldenseal, but not kava kava, inhibits human CYP3A activity in vivo. Clin Pharmacol Ther 2008;83:61–69. PubMed 17495878
      5. Nguyen JT et al. Assessing transporter-mediated natural product–drug interactions via in vitro–in vivo extrapolation: clinical evaluation with a probe cocktail. Clin Pharmacol Ther 2021;109:1342–1352. PubMed 33174626
      6. NCCIH. Goldenseal (February 2025). nccih.nih.gov
      7. FDA. Grapefruit juice and some drugs don’t mix (content current as of July 1, 2021). fda.gov
      8. Misaka S et al. Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. Clin Pharmacol Ther 2014;95:432–438. PubMed
      9. Misaka S et al. Limited sampling strategy for predicting the area under plasma concentration–time curve of nadolol in healthy subjects. J Clin Pharmacol 2025;65:621–627. PubMed 39551720
      10. NCCIH. Green tea (February 2025). nccih.nih.gov
      11. NCCIH. Red yeast rice (November 2022). nccih.nih.gov
      12. NCCIH. Garlic (February 2025). nccih.nih.gov
      13. NCCIH. Echinacea (November 2024). nccih.nih.gov

      Only a pharmacist or clinician who knows your medicines can say whether any of this applies to you. Absence from this list does not mean a botanical has no interactions.

      Evidence map

      What the research says about 15 popular botanicals, in NCCIH’s words

      Each chip is one statement from the U.S. National Center for Complementary and Integrative Health (NCCIH) fact sheet for that botanical. EUTECNIQ sorted the statements into four groups by their wording; the quote is shown so you can judge the sorting. A group describes how strong the evidence is, not how large an effect is. Botanicals in your list are marked.

      51 statements at a glance. Each block is one group; the number is how many statements fall in it. Tap a botanical to open its quotes.

      Some evidence of benefit (9)Early or limited evidence (13)Unclear, mixed or too little evidence (22)Evidence of no benefit (7)

      Show the 15 botanicals and NCCIH’s statementsOne chip per statement, sorted into four evidence groups
      NCCIH statements on 15 botanicals, sorted by EUTECNIQ into four evidence groups
      Botanical · NCCIH page updatedSome evidence of benefitEarly or limited evidenceUnclear, mixed or too little evidenceEvidence of no benefit
      Turmeric, curcuminCurcuma longaApril 2025
      GinkgoGinkgo bilobaFebruary 2025
      Green teaCamellia sinensisFebruary 2025
      St. John’s wortHypericum perforatumMay 2025
      Red yeast riceMonascus purpureusNovember 2022
      EchinaceaEchinacea purpurea, E. angustifoliaNovember 2024
      AshwagandhaWithania somniferaMarch 2023
      GarlicAllium sativumFebruary 2025
      GingerZingiber officinaleFebruary 2025
      ValerianValeriana officinalisMay 2025
      Milk thistleSilybum marianumFebruary 2025
      Saw palmettoSerenoa repensApril 2025
      Black cohoshActaea racemosaNovember 2024
      CranberryVaccinium macrocarponNovember 2024
      GoldensealHydrastis canadensisFebruary 2025

      Choose a statement to read NCCIH’s exact words and the source.

      All 51 statements, as quoted
      Turmeric, curcumin · NCCIH, last updated April 2025
      Knee osteoarthritis, oral · Early or limited evidence: “The initial evidence is positive; higher-quality evidence is needed to reach definitive conclusions, and more research is needed to understand the impact of bioavailability on curcumin’s effects.”
      Fatty liver disease (NAFLD) measures · Early or limited evidence: “Initial research suggests that oral turmeric or curcumin might improve some NAFLD measures, but it’s unclear which specific measures are consistently improved.”
      Oral mucositis from cancer treatment · Early or limited evidence: “Initial research suggests that turmeric or curcumin in an oral or mouthwash formulation might improve symptoms of oral mucositis (tissue swelling and irritation in the mouth) related to cancer treatment.”
      Knee osteoarthritis pain, topical · Unclear, mixed or too little evidence: “It’s unclear whether topical curcumin ointment has an effect on pain related to knee osteoarthritis.”
      Safety: “Highly bioavailable formulations of curcumin, which enhance the body’s ability to absorb the curcumin, may harm your liver.”
      Ginkgo · NCCIH, last updated February 2025
      Preventing or slowing dementia · Evidence of no benefit: “Ginkgo has not been shown to be beneficial for preventing or slowing the progression of dementia.”
      Dementia symptoms · Unclear, mixed or too little evidence: “Ginkgo extract may have a modest benefit for dementia symptoms, particularly at relatively high doses, but the evidence is inconsistent.”
      Cognitive performance in healthy people · Unclear, mixed or too little evidence: “Although dietary supplements containing ginkgo have been marketed for “brain health,” it’s uncertain whether they actually influence cognitive performance in healthy people.”
      Anxiety, PMS, schizophrenia, vertigo · Early or limited evidence: “For various health conditions, including anxiety, PMS, schizophrenia, and vertigo, a small amount of evidence suggests a benefit from taking ginkgo orally (by mouth), but the overall evidence is not conclusive.”
      Heart disease, blood pressure, tinnitus, multiple sclerosis · Evidence of no benefit: “Research suggests that ginkgo is not helpful for preventing heart disease, treating high blood pressure, or relieving symptoms of tinnitus or multiple sclerosis.”
      Safety: “Fresh ginkgo seeds are toxic when consumed orally, and serious side effects have also occurred in people who consumed roasted ginkgo seeds or the crude ginkgo plant.”
      Green tea · NCCIH, last updated February 2025
      Cancer risk · Unclear, mixed or too little evidence: “Many studies have looked at the relationship between green tea consumption and the risk of various types of cancer. The overall results of these studies have been inconsistent.”
      Coronary heart disease · Unclear, mixed or too little evidence: “In Asian populations but not in Western populations, green tea consumption has been linked to a lower risk of coronary heart disease.”
      Body weight · Some evidence of benefit: “The catechins and caffeine in green tea and its extracts may have a modest effect on body weight. However, the effects of green tea products may vary depending on the composition of the product and the individual’s level of physical activity.”
      Total and LDL cholesterol · Some evidence of benefit: “Green tea reduced total cholesterol and low-density lipoprotein (LDL) cholesterol to a small extent, but it did not affect high-density lipoprotein (HDL) cholesterol or triglycerides.”
      Safety: “Although uncommon, liver injury has been reported in some people who used green tea products, primarily green tea extracts in tablet or capsule form.”
      St. John’s wort · NCCIH, last updated May 2025
      Mild or moderate depression · Some evidence of benefit: “St. John’s wort appears to be more effective than a placebo (an inactive substance) and as effective as standard antidepressant medications for mild or moderate depression.”
      Severe depression, or longer than 12 weeks · Unclear, mixed or too little evidence: “It’s uncertain whether this is true for severe depression or for time periods longer than 12 weeks.”
      Menopausal hot flashes; somatic symptom disorder · Early or limited evidence: “Small numbers of studies suggest that St. John’s wort may be helpful for hot flashes associated with menopause and for somatic symptom disorder (a condition involving intense anxiety about physical symptoms).”
      ADHD, IBS, OCD, PMS, smoking cessation, wound healing · Unclear, mixed or too little evidence: “However, only a small amount of research has been done on the use of St. John’s wort for each of these purposes, and the evidence hasn’t clearly shown it to be helpful for any of them.”
      Safety: “It has been clearly shown that St. John’s wort can interact in dangerous, sometimes life-threatening ways with a variety of medicines.”
      Red yeast rice · NCCIH, last updated November 2022
      Cholesterol, products with considerable monacolin K · Some evidence of benefit: “Red yeast rice products that have considerable amounts of monacolin K may effectively lower blood cholesterol levels, blood glucose levels, and blood pressure. […] But, because of the levels of monacolin K, these products are considered by the FDA to be unapproved new drugs and are not sold legally in the United States.”
      Products with little monacolin K · Unclear, mixed or too little evidence: “Other red yeast rice products may contain very little monacolin K, and it’s unknown if these products are effective in reducing cholesterol levels or improving other areas of health.”
      Safety: “Some red yeast rice products contain a contaminant called citrinin, which is toxic and can damage the kidneys.”
      Echinacea · NCCIH, last updated November 2024
      Catching a cold · Early or limited evidence: “Taking echinacea may slightly reduce your chances of catching a cold. […] More research is needed to confirm these findings.”
      Length of a cold · Unclear, mixed or too little evidence: “It’s still unclear whether echinacea can shorten the length of a cold.”
      Respiratory infections in children · Unclear, mixed or too little evidence: “One recent study found that echinacea might reduce the chance of respiratory tract infection and associated complications in children, but overall, there isn’t enough evidence to support a clear connection.”
      Safety: “However, some people have allergic reactions to echinacea, which may be severe.”
      Ashwagandha · NCCIH, last updated March 2023
      Insomnia and stress · Some evidence of benefit: “Research shows that some ashwagandha preparations may be effective for insomnia and stress.”
      Anxiety · Unclear, mixed or too little evidence: “However, evidence is unclear about its effects on anxiety.”
      Testosterone and sperm quality · Early or limited evidence: “There is some limited evidence that suggests that taking ashwagandha for 2 to 4 months may increase testosterone levels and sperm quality.”
      Asthma, athletic performance, cognition, diabetes, menopause, female infertility · Unclear, mixed or too little evidence: “There isn’t enough evidence to determine if ashwagandha is helpful for any other health conditions, such as asthma, athletic performance, cognitive function, diabetes, menopause, and female infertility.”
      Safety: “Although it is rare, there have been a number of cases that link liver injury to ashwagandha supplements.”
      Garlic · NCCIH, last updated February 2025
      Cholesterol, in people with high levels · Some evidence of benefit: “Garlic supplements may reduce levels of total cholesterol and low-density lipoprotein (LDL) cholesterol to a small extent in people who have high blood cholesterol levels.”
      Blood pressure, in people with high blood pressure · Early or limited evidence: “Limited evidence suggests that garlic supplements may reduce blood pressure to a small extent in people who have high blood pressure.”
      Blood sugar, in people with diabetes · Some evidence of benefit: “Garlic supplements may reduce blood sugar to a small extent in people with diabetes.”
      Stomach cancer risk · Evidence of no benefit: “Consuming garlic does not seem to reduce the risk of stomach cancer.”
      Colorectal cancer risk · Unclear, mixed or too little evidence: “It’s uncertain whether garlic influences the risk of colorectal cancer.”
      Immune support in cold and flu season · Unclear, mixed or too little evidence: “However, very little research has been done on this topic.”
      Safety: “Taking garlic supplements may increase the risk of bleeding.”
      Ginger · NCCIH, last updated February 2025
      Nausea and vomiting of pregnancy · Some evidence of benefit: “Research shows that ginger may be helpful for nausea and vomiting associated with pregnancy.”
      Motion sickness · Evidence of no benefit: “Most studies of ginger for motion sickness haven’t shown it to be helpful.”
      Nausea from chemotherapy or after surgery · Unclear, mixed or too little evidence: “It’s uncertain whether ginger is a helpful addition to standard treatments for nausea and vomiting associated with cancer chemotherapy and whether it’s helpful for nausea and vomiting after surgery.”
      Menstrual cramps · Early or limited evidence: “Research suggests that ginger dietary supplements might be helpful for reducing the severity of menstrual cramps.”
      Knee osteoarthritis, oral · Early or limited evidence: “Ginger dietary supplements might be helpful for symptoms of knee osteoarthritis, but much of the research has been of poor quality.”
      Knee osteoarthritis, topical · Evidence of no benefit: “Ginger used topically (applied to the skin) has not been shown to be helpful for knee osteoarthritis symptoms.”
      Valerian · NCCIH, last updated May 2025
      Sleep problems · Unclear, mixed or too little evidence: “The evidence on whether valerian is helpful for sleep problems is inconsistent. In its 2017 clinical practice guidelines, the American Academy of Sleep Medicine recommended against using valerian for chronic insomnia in adults.”
      Menopause symptoms · Early or limited evidence: “Three small studies suggest that valerian might be helpful for menopause symptoms, but there is not enough evidence to know for certain.”
      Anxiety, depression, PMS, menstrual cramps, stress · Unclear, mixed or too little evidence: “There’s not enough evidence to allow any conclusions about whether valerian is helpful for anxiety, depression, premenstrual syndrome, dysmenorrhea (menstrual cramps), stress, or other conditions.”
      Milk thistle · NCCIH, last updated February 2025
      Blood sugar in type 2 diabetes · Early or limited evidence: “Results from a small number of studies in people show that milk thistle extracts may help to control blood sugar in people with type 2 diabetes. Most of this research was done in Middle Eastern countries, and it is unclear whether the same results would be seen in other parts of the world.”
      Liver diseases · Unclear, mixed or too little evidence: “Results from clinical trials of milk thistle for liver diseases, such as alcohol-related liver disease, hepatitis B and C, non-alcoholic fatty liver disease, and liver problems caused by cancer chemotherapy, low oxygen levels, or toxins have been conflicting or too limited to allow conclusions to be reached.”
      Breast milk production · Unclear, mixed or too little evidence: “It is unclear whether milk thistle has an effect on breast milk production.”
      Saw palmetto · NCCIH, last updated April 2025
      Enlarged prostate (BPH) symptoms · Evidence of no benefit: “A 2023 review of 27 studies on saw palmetto in men with BPH found that this herb, when administered alone, provides little or no benefit for BPH symptoms.”
      Chronic prostatitis or pelvic pain · Evidence of no benefit: “A 2022 review of five studies on saw palmetto for chronic prostatitis/chronic pelvic pain syndrome did not find a significant benefit of the herb in patients with this condition.”
      Male-pattern hair loss · Unclear, mixed or too little evidence: “The evidence is too limited to allow conclusions to be reached.”
      Black cohosh · NCCIH, last updated November 2024
      Menopause symptoms, hot flashes · Some evidence of benefit: “A 2023 review of 22 studies of products containing black cohosh extracts, alone or in combination with other herbs, found that they were potentially beneficial for overall menopause symptoms. Data on specific symptoms showed improvements in hot flashes but not anxiety or depressive symptoms.”
      Hot flashes from breast cancer treatment · Unclear, mixed or too little evidence: “It’s uncertain whether black cohosh can reduce hot flashes related to breast cancer treatment.”
      Cranberry · NCCIH, last updated November 2024
      Recurrent urinary tract infections in women · Early or limited evidence: “In general, cranberry products may decrease the overall risk of symptomatic, recurrent UTIs in women by 25 percent, and in some cases, by more than 30 percent. However, the effectiveness of cranberry is still in question because of inconsistent findings.”
      Goldenseal · NCCIH, last updated February 2025
      Any health condition · Unclear, mixed or too little evidence: “There is not enough evidence to determine whether goldenseal is useful for any health conditions. More research would be needed before any conclusions can be reached.”
      Safety: “Goldenseal may change the way your body processes many medications.”

      Method: “some evidence of benefit” where NCCIH says a botanical appears effective, research shows it may help, or it reduced a measure; “early or limited” where NCCIH says initial, small or limited research suggests a benefit; “unclear, mixed or too little” where NCCIH says results are inconsistent, conflicting, uncertain or insufficient; “no benefit” where NCCIH says it has not been shown to help or was not helpful. NCCIH pages downloaded November 8, 2026; NCCIH material is in the public domain.

      How it reads a label

      The conversions, and where each comes from

      Try a conversion. The same factors the calculator uses, with their sources.

      Show the unit conversionsHow IU, DFE, RAE and mineral salts are converted, and the source for each
      Unit conversions used by the calculator
      On the labelConverted toFactorSource
      Vitamin D, IUµg1 µg = 40 IUNIH ODS, vitamin D fact sheet
      Vitamin E, IU, natural form (d-alpha, RRR)mg alpha-tocopherol× 0.67NIH ODS, vitamin E fact sheet
      Vitamin E, IU, synthetic form (dl-alpha, all-rac)mg alpha-tocopherol× 0.45NIH ODS, vitamin E fact sheet
      Vitamin A, IU, retinol or retinyl estersµg RAE× 0.3NIH ODS, vitamin A fact sheet
      Vitamin A, IU, beta-carotene from supplementsµg RAE× 0.3; not counted toward the ULNIH ODS, vitamin A fact sheet
      Folic acid or methylfolate, µgµg DFE× 1.7FDA, Converting Units of Measure (2019); 1.7 is the stated maximum for synthetic folate
      Mineral, “(as … )” on a U.S. Supplement Facts panelthe mineral itselfnone: the label already gives the element21 CFR 101.36(b)(2)(ii)
      Mineral compound by weightelemental mineralatomic mass × count ÷ molar mass of the formulaIUPAC standard atomic weights; formula shown with each result
      Extract, n:1 ratiostarting plant weightextract × nArithmetic; a ratio is not a measure of strength
      Limits

      What it does not do

      Method

      Reference values and sources

      Show the reference values and sourcesU.S. and EU upper levels and where each comes from
      U.S. values
      Recommended Dietary Allowances, Adequate Intakes and Tolerable Upper Intake Levels from the National Academies’ Dietary Reference Intakes summary tables (NCBI Bookshelf NBK545442), including what each UL covers: preformed vitamin A only; alpha-tocopherol, niacin and folate from supplements and fortified foods; magnesium from supplements and medicines only.
      EU values
      EFSA, Overview on Tolerable Upper Intake Levels, version 11, August 2025, for adults. Iron, manganese and fluoride have safe levels of intake, not ULs.
      Caffeine, EGCG, monacolins
      FDA, Spilling the Beans (400 mg a day for healthy adults); EFSA 2015 caffeine opinion (200 mg single doses; 400 mg a day; 200 mg a day in pregnancy and lactation; 3 mg/kg a day for children); EFSA 2018 on green tea catechins; Regulation (EU) 2022/860 on monacolins from red yeast rice; NCCIH on red yeast rice and St. John’s wort.
      Product labels
      NIH Office of Dietary Supplements, Dietary Supplement Label Database, through its public Label API (version 9; data CC0 1.0). Each label is converted line by line into the label reader, with its forms, so you can check every line before it is added.
      Foods
      U.S. Department of Agriculture, Agricultural Research Service. FoodData Central: Food and Nutrient Database for Dietary Studies (FNDDS) 2021–2023, survey foods, CSV release of October 31, 2024 (5,432 foods; public domain, CC0 1.0). Values per 100 g and FNDDS portion weights, as published.
      Interactions
      FDA table of substrates, inhibitors and inducers (May 29, 2026); FDA consumer update on grapefruit juice (2021); NCCIH fact sheets; and the clinical studies cited in the explainer, read in the original abstracts.
      Evidence map
      NCCIH fact sheets for 15 botanicals, quoted verbatim, with each page’s “last updated” date.
      Languages
      The interface is available in Spanish, French, Portuguese, Chinese (Simplified) and Hindi, translated by EUTECNIQ. Notes, the explainer, the quotes and the sources stay in English, the reference version.
      Offline
      After the first visit, the page, its data and the food table are kept by your browser so the calculator also works without a connection. The label search needs a connection.
      Privacy
      The list is kept in this browser’s storage under one key and in any file you save. The page sends nothing to EUTECNIQ; a label search sends only the words you type to the NIH API. Clearing the list or your browser data deletes it.
      Checked
      Every reference value, quote and study figure was checked against the sources above on November 8, 2026. Values change; the sources are authoritative.

      Health information notice

      These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

      Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

      EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

      Ready to check what you take?

      Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.